Stock Track | Cellebrite Soars 21.35% on Strong Q3 Results, Raised Guidance, and Analyst Upgrades

Stock Track
Nov 13

Shares of Cellebrite (CLBT), a leading digital intelligence solutions provider, surged 21.35% in pre-market trading on Thursday following the release of impressive third-quarter 2025 financial results and an optimistic future outlook.

The company reported Q3 revenue of $126.03 million, surpassing analyst expectations of $122.01 million and marking an 18% year-over-year increase. Cellebrite's adjusted EBITDA of $37.74 million also outperformed expectations, resulting in an adjusted EBITDA margin of 29.9%. Key drivers of Cellebrite's success included a 21% growth in subscription revenue, fueled by strong demand in U.S. state and local markets, as well as in Latin America. CEO Thomas E. Hogan highlighted significant expansion within the U.S. Federal business segment, which contributed to the overall growth.

In response to the strong performance, Cellebrite raised its full-year 2025 revenue guidance to between $470 million and $475 million, representing a 17% to 18% annual growth. This optimistic outlook, coupled with the robust Q3 results, has instilled confidence in investors and analysts alike. Several financial institutions, including JP Morgan, Deutsche Bank, and Bank of America, have raised their price targets for Cellebrite stock, with targets now ranging from $24 to $25 per share. The company's strategic focus on enhancing its Digital Investigation Platform, as evidenced by its recent Autumn 2025 Release, further solidifies its market position and growth prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10